Magazines
Newsletter
Advertise
Search
The Business Magazine - B2B Business News - Site Logo
The Business Magazine - B2B Business News - Site Logo
The Business Magazine July 2024
Read now
PICK YOUR EDITION

GenomeKey awarded $11.4M to transform sepsis diagnosis and treatment

The Business Magazine article image for: GenomeKey awarded $11.4M to transform sepsis diagnosis and treatment
GenomeKey 
1 August 2024
GenomeKey 

GenomeKey has been awarded a major grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to build a functioning, automated prototype of their desktop diagnostic device.

The Bristol-based company joined the SETSQUARED incubation programme in 2020 with a vision to build an in vitro diagnostic device that would completely transform the way we diagnose and treat sepsis and other bacterial infections.

GenomeKey’s next-generation device will be able to detect and identify bacteria directly from patient blood, delivering a full antimicrobial resistance (AMR) profile in just hours.

Dr Michael Roberts, GenomeKey CEO, said: “We have a vision of the world where nobody dies from a treatable infection. Right now, the gold standard test takes too long and has a high false-negative rate. We’re giving clinicians the information they need, much faster, so they can deliver rapid diagnostics testing and precision medicine for a more targeted treatment.

“We live in an exciting time for medical science, where the twin revolutions in next generation sequencing and machine learning now make it possible for us to identify and profile bacteria directly from patient blood, accurately and cheaply. We’re on a mission to save lives, improve outcomes and fight the global threat of antimicrobial resistance.”

Since its founding in 2016, CARB-X has provided more than US$450M to more than 100 projects to address bacterial infections. These projects include vaccines, rapid diagnostics, antibiotics, and other non-traditional therapeutics and preventatives. The CARB-X portfolio is the world’s most scientifically diverse antibacterial R&D portfolio.

Erin Duffy, Chief of R&D at CARB-X, said: “It is imperative to direct treatment quickly with the right antibiotic treatment, and GenomeKey’s technology has the potential to help practitioners direct the appropriate treatment by delivering a phenotypic antibiotic sensitivity prediction based on rapid whole genome sequencing direct from blood.”


Share 

Nicky Godding is editor of The Business Magazine. Before her journalism career, she worked mainly in public relations moving into writing when she was invited to launch Retail Watch, a publication covering retail and real estate across Europe.

After some years of constant travelling, she tucked away her passport and concentrated on business writing, co-founding a successful regional business magazine. She has interviewed some of the UK’s most successful entrepreneurs who have built multi-million-pound businesses and reported on many science and technology firsts.

She reports on the region’s thriving business economy from start-ups, family businesses and multi-million-pound corporations, to the professionals that support their growth and the institutions that educate the next generation of business leaders.

Latest deal ticket

All deals

Events

All events

Related news


Group Titles

Dorset BIZ NewsHampshire BIZ News
crossmenu